The U.S. Drug Enforcement Administration’s plan to propose reclassifying marijuana as a less dangerous drug will allow licensed cannabis businesses to claim a valuable tax break and encourage more cannabis research, but it is unlikely to have a major effect on state regulatory programs.
The proposed move from Schedule I, the highest federal drug classification, down to Schedule III would put psychoactive cannabis on par with drugs with accepted medical uses and low to moderate addiction potential, such as ketamine.
Already a subscriber? Sign in